In patients with AD, phosphorylated cPLA2 levels were significantly greater in APOE3/E4 carriers compared with APOE3/E3 carriers, while the total cPLA2 levels did not differ between the two groups (Fig. 4B). Here, PLA2G4A is linked to Alzheimer disease.